Effects of raloxifene on lipid and lipoprotein levels in postmenopausal osteoporotic women with and without hypertriglyceridemia

Metabolism: Clinical and Experimental

Volumn 55, Issue 7, 2006, Pages 972-979

  Dayspring, Thomas ^a   Qu, Yongming ^b   Keech, Cheryl ^b  

^a North Jersey Institute of Menopausal Lipidology   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RALOXIFENE;

AGED; ARTHRITIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; ENDOMETRIUM POLYP; FEMALE; FLUSHING; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INSOMNIA; LEG EDEMA; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MUSCLE CRAMP; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SIDE EFFECT; THERAPY EFFECT; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; VENOUS THROMBOEMBOLISM; VERTIGO; WEIGHT REDUCTION;

EID: 33745153345     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2006.03.005     Document Type: Article

References (39)

1. American Heart Association. 2002 Heart and stroke statistical update. Available at:. www.americanheart.org
2. Hokanson J.E., and Austin M.A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 3 (1996) 213-219
3. Lloyd-Jones D.M., O'Donnell C.J., D'Agostino R.B., et al. Applicability of cholesterol-lowering primary prevention trials to a general population: the Framingham Heart Study. Arch Intern Med 161 (2001) 949-954
4. Assmann G., Schulte H., Funke H., et al. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J 19 Suppl M (1998) M8-M14
5. Austin M.A., Hokanson J.E., and Edwards K.L. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 81 (1998) 7B-12B
6. Austin M.A. Plasma triglyceride and coronary heart disease. Arterioscler Thromb 11 (1991) 2-14
7. Executive Summary of The Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
8. Havel R.J., and Rapaport E. Management of primary hyperlipidemia. N Engl J Med 332 (1995) 1491-1498
9. Krauss R.M. Atherogenicity of triglyceride-rich lipoproteins. Am J Cardiol 81 (1998) 13B-17B
10. Dayspring T.D. Coronary heart disease in women: triglycerides and lipoprotein biology. J Gend Specif Med 5 (2002) 27-33
11. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280 (1998) 605-613
12. Lobo R.A., Bush T., Carr B.R., and Pickar J.H. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil Steril 76 (2001) 13-24
13. Kuller L.H. Hormone replacement therapy and risk of cardiovascular disease: implications of the results of the Women's Health Initiative. Arterioscler Thromb Vasc Biol 23 (2003) 11-16
14. Evista package insert (2001), Eli Lilly and Company, Indianapolis (Ind)
15. Mosca L., Harper K., Sarkar S., et al. Effect of raloxifene on serum triglycerides in postmenopausal women: influence of predisposing factors for hypertriglyceridemia. Clin Ther 23 (2001) 1552-1565
16. Barrett-Connor E., Grady D., Sashegyi A., et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 287 (2002) 847-857
17. Moriarty P.M. Using both "relative risk reduction" and "number needed to treat" in evaluating primary and secondary clinical trials of lipid reduction. Am J Cardiol 87 (2001) 1206-1208
18. Walsh B.W., Kuller L.H., Wild R.A., et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 279 (1998) 1445-1451
19. Walsh B.W., Paul S., Wild R.A., et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 85 (2000) 214-218
20. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
21. Davis R.A. Cell and molecular biology of the assembly and secretion of apolipoprotein B-containing lipoproteins by the liver. Biochim Biophys Acta 1440 (1999) 1-31
22. Walldius G., Jungner I., Holme I., et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358 (2001) 2026-2033
23. Gotto Jr. A.M., Whitney E., Stein E.A., et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 101 (2000) 477-484
24. Pedersen T.R., Olsson A.G., Faergeman O., et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 97 (1998) 1453-1460
25. Gardner C.D., Fortmann S.P., and Krauss R.M. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 276 (1996) 875-881
26. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 44 (2004) 720-732
27. Cui Y., Blumenthal R.S., Flaws J.A., et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 161 (2001) 1413-1419
28. Grundy S.M. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation 106 (2002) 2526-2529
29. Knopp R.H. Drug treatment of lipid disorders. N Engl J Med 341 (1999) 498-511
30. Insull W., Davidson M.H., Kulkarni P.M., et al. Effects of raloxifene and low-dose simvastatin coadministration on plasma lipids in postmenopausal women with primary hypercholesterolemia. Metabolism 54 (2005) 939-946
31. Gotto Jr. A.M. Contemporary diagnosis and management of lipid disorders (1999), Handbooks in Health Care, Newtown (Pa)
32. Carr M.C., Knopp R.H., Brunzell J.D., et al. Effect of raloxifene on serum triglycerides in women with a history of hypertriglyceridemia while on oral estrogen therapy. Diabetes Care 28 (2005) 1555-1561
33. Asztalos B.F., Collins D., Cupples L.A., et al. Value of high density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol 25 (2005) 2185-2191
34. Knopp R.H., Zhu X., and Bonet B. Effects of estrogens on lipoprotein metabolism and cardiovascular disease in women. Atherosclerosis 110 Suppl (1994) S83-S91
35. Wakatsuki A., Ikenoue N., Izumiya C., et al. Effect of estrogen and simvastatin on low-density lipoprotein subclasses in hypercholesterolemic postmenopausal women. Obstet Gynecol 92 (1998) 367-372
36. Wakatsuki A., Ikenoue N., Okatani Y., et al. Estrogen-induced small low density lipoprotein particles may be atherogenic in postmenopausal women. J Am Coll Cardiol 37 (2000) 425-430
37. Baetta R., Comparato C., Altana C., et al. Raloxifene reduces macrophage accumulation and matrix metalloproteinase expression in carotid lesions of ovariectomized, cholesterol-fed rabbits. Circulation 104 (2001) II-67
38. Simoncini T., and Genazzani A.R. Raloxifene acutely stimulates nitric oxide release from human endothelial cells via an activation of endothelial nitric oxide synthase. J Clin Endocrinol Metab 85 (2000) 2966-2969
39. Colacurci N., Manzella D., Fornaro F., et al. Endothelial function and menopause: effects of raloxifene administration. J Clin Endocrinol Metab 88 (2003) 2135-2140